0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Medical News and Perspectives |

Open Access to Data Closes the Book on Efficacy of Popular Bone-Graft Device

Mike Mitka, MSJ
JAMA. 2013;310(4):359-360. doi:10.1001/jama.2013.8485.
Text Size: A A A
Published online

Extract

New studies suggest a popular spinal bone-graft device has no clinical advantages over traditional bone grafting methods for reducing chronic lower back pain. Perhaps as important, the way these studies came about suggests a better approach to conducting postmarketing surveillance of medical devices and drugs.

The device in question is the Infuse Bone Graft, manufactured by Medtronic. It uses recombinant human bone morphogenetic protein 2 (rhBMP-2), a genetically engineered protein with bone growth–stimulating properties, as a bone graft substitute. The rhBMP-2 device was approved in 2002 by the US Food and Drug Administration (FDA) for anterior lumbar interbody fusion surgery to reduce chronic low back pain. Earlier studies found rhBMP-2 to be superior to other grafting therapies, and the device was soon generating almost $1 billion in annual revenues for Medtronic.

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption

Graphic Jump LocationImage not available.

The Infuse Bone Graft, which uses recombinant human bone morphogenetic protein 2, offers no clinical advantages compared with standard bone grafting, new research finds.

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
New grafting procedure for oral implantation. J Calif Dent Assoc 2014;42(7):440.
Orthodontic forced eruption: a team approach in aesthetic treatment. Dent Today 2014;33(7):112, 114, 116; quiz 117.
Jobs
brightcove.createExperiences();